Mesothelioma Legal News

The U.S. Environmental Protection Agency released Part 1 of its Final Risk Evaluation for Asbestos, reaffirming preliminary findings from March that were roundly criticized for underestimating the dangers of exposure to this toxic mineral. Six ongoing use categories of asbestos were evaluated by the EPA, which found 16 conditions of use that presented unreasonable risk…

The post EPA Evaluation Finds Asbestos Still An Unreasonable Risk appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

United States District Judge Edward Chen has ordered the Environmental Protection Agency to improve its data collection on the amount of asbestos and asbestos products that are coming into the country. Chen issued his ruling Tuesday in San Francisco, stemming from a lawsuit brought against the EPA by a group of nonprofit organizations wanting to…

The post Judge Rules EPA Must Tighten Asbestos Data Collection appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope. Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various…

The post Top 10 Mesothelioma and Asbestos News Stories of 2020 appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing…

The post Study: Immunotherapy Vaccine for Mesothelioma Still Promising appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The University of Sheffield has launched the Mesothelioma UK Research Centre-Sheffield, the country’s first experience-based program designed to improve the treatment and care of patients diagnosed with this aggressive, asbestos-related cancer. Based in South Yorkshire, England, the University of Sheffield hopes to become an international pioneer in patient-led mesothelioma research. “The program will build on…

The post Mesothelioma Patient Research Expanding in United Kingdom appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Removing major organs to achieve a more complete cancer resection did not increase severe complications or hinder survival benefits of aggressive surgery for patients with peritoneal mesothelioma, according to a recent report. The increased complexity of organ resection surgery will not adversely affect long-term outcomes, according to the multicenter study published in Annals of Surgical…

The post Mesothelioma Surgery with Organ Removal Extends Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Gold nanotubes – tiny hollow cylinders one thousandth the width of a human hair – could be used to treat mesothelioma, a type of cancer caused by exposure to asbestos, according to a team of researchers.

Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR…

The post Latest T-Cell Clinical Trial Opens for Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. House of Representatives last week failed to advance once-promising legislation that effectively would have banned asbestos, frustrating advocates once again. H.R. 1603, titled the Alan Reinstein Ban Asbestos Now Act of 2020, had been expected to pass easily under a Congressional procedure reserved for broadly supported, non-controversial legislation. The bipartisan House Committee on…

The post Congress Fails to Vote on Asbestos Ban Legislation appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle an more than a thousand lawsuits claiming its iconic baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson & Johnson, the world’s largest…

The post Johnson & Johnson Settles 1K Baby Powder-Asbestos Lawsuits appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the…

The post FDA Approves Opdivo, Yervoy Combination for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

While the incidence of malignant mesothelioma in the United States continued its gradual decline, the tendency to sue for damages drastically increased in recent years, according to a KCIC study. Lawsuits filed by those stricken with the deadly asbestos-related cancer increased 65.7% from 2007 to 2017. Meanwhile, the overall incidence rate of mesothelioma dropped 16.2%…

The post KCIC Report: Mesothelioma Lawsuits on the Rise in US appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A much-anticipated, phase III clinical trial studying the use of gene therapy to combat pleural mesothelioma cancer has made a promising start. Interest is growing in what many believe could soon change the standard of care for this aggressive cancer with no cure. “I would definitely encourage patients to give this one a try,” Dr….

The post Gene Therapy Clinical Trial for Mesothelioma Moving Forward appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied…

The post Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The Science Advisory Committee on Chemicals found considerable failings and an underestimation of danger to the general public in a draft risk evaluation of asbestos submitted earlier this year by the U.S. Environmental Protection Agency. SACC, which serves as a scientific, peer-review mechanism for the EPA, released its recommendations last week in the ongoing governmental…

The post Peer Review Finds EPA’s Asbestos Risk Evaluation Flawed appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.